AERI - Aerie Pharmaceuticals, Inc.
| Previous close | 12.00 |
| Open | 12.32 |
| Bid | 12.84 x 800 |
| Ask | 12.86 x 800 |
| Day's range | 11.92 - 12.92 |
| 52-week range | 10.80 - 46.28 |
| Volume | 556,953 |
| Avg. volume | 1,000,246 |
| Market cap | 587.321M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.39 |
| Earnings date | 19 Feb 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.75 |
- Business Wire
Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:50 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
- Zacks
Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Aerie Pharmaceuticals, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates
A week ago, Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) came out with a strong set of full-year numbers that could...
- Business Wire
Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Cowen 40th Annual Healthcare Conference on Monday, March 2, 2020 at 12:00 p.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and provide a business update.
- Zacks
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
- Zacks
Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -28.00% and 24.17%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2019, along with 2020 guidance and a general business update.
- Business Wire
Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced the appointment of Nina Ohara, PharmD, M.B.A., as Director, Marketing, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Dr. Ohara will lead and support the development of strategies, programs and communication plans for the payer markets and manage all aspects of reimbursement to drive appropriate adoption of Rhopressa® and Rocklatan® in the United States. She most recently held a related position at Avanir Pharmaceuticals, Inc., a subsidiary of Otsuka Pharmaceuticals, Inc. Aerie also announced the appointment of Gregory Jones, CPA, as Director, Tax, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Jones will be responsible for all global tax related functions at Aerie. He most recently held a related position at Deloitte Tax, LLP.
- Business Wire
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2019 financial results will be released after the market closes on Thursday, February 20, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
- Simply Wall St.
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI): Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses...
- Business Wire
Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced the appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, M.D., M.B.A., Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and medical affairs strategy for the Company. She most recently served as Executive Director of Ophthalmology at Allergan, where she oversaw the clinical development of pharmaceutical, consumer and device products for anterior and posterior segment diseases. Prior to joining Allergan, Dr. Senchyna held leadership positions in R&D and Medical Affairs at Alcon and Panoptica, with focus on anterior segment and biomarker discovery. She began her career as an Associate Professor at the University of Waterloo, School of Optometry with research focused on ocular surface diseases and contact lens biomaterial development. She is an author on more than 40 peer-reviewed publications, has given more than 60 presentations nationally and internationally, and holds multiple patents. Dr. Senchyna earned both a BSc. and Ph.D. from McMaster University.
- Simply Wall St.
Does Aerie Pharmaceuticals (NASDAQ:AERI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- Zacks
Aerie's (AERI) Application for Roclanda Accepted in Europe
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
- Zacks
Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Zacks
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
